Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05067114 · ClinicalTrials.gov registry record

Solutions for Atrial Fibrillation Edvocacy (SAFE)

A clinical trial of Cardiovascular Diseases and Atrial Fibrillation, sponsored by American Pharmacists Association Foundation.

Completed
Registry status
650
Enrollment target
1
Study location

NCT05067114: Completed study of Cardiovascular Diseases and Atrial Fibrillation, sponsored by American Pharmacists Association Foundation.

NCT05067114 is a study of Cardiovascular Diseases and Atrial Fibrillation that has completed, run by American Pharmacists Association Foundation. The registered enrollment target is 650 participants, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05067114, a study of Cardiovascular Diseases and Atrial Fibrillation, has completed, sponsored by American Pharmacists Association Foundation.

COMPLETED
Registry status
650 participants
Enrollment target
1
Study location

Study Summary

The aim of this demonstration project is to create an additional access point in the community at local pharmacies for atrial fibrillation screening, detection, and referral to physicians for follow-up and initiation of evidence-based therapy when appropriate.

Primary Outcome

Number of Afib screening tests performed in the pharmacy

Interventions

  • DEVICE Screening, detection and referral for atrial fibrillation

Study Locations (1)

District of Columbia

  • Central Study Sponsor Facility - Washington D.C.

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2021-09-03
Est. Completion 2022-06-30

What the finished NCT05067114 record still lists

NCT05067114 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Screening, detection and referral for atrial fibrillation is the first listed.

NCT05067114 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05067114 about?

NCT05067114 is a clinical study titled "Solutions for Atrial Fibrillation Edvocacy (SAFE)". The aim of this demonstration project is to create an additional access point in the community at local pharmacies for atrial fibrillation screening, detection, and referral to physicians for follow-up and initiation of evidence-based therapy when appropriate.

What is the current status of trial NCT05067114?

This trial is currently completed. The enrollment target is 650 participants. The study started on 2021-09-03. Estimated completion is 2022-06-30.

What conditions does trial NCT05067114 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Atrial Fibrillation, Cardiac Arrhythmia.

What interventions are being tested in trial NCT05067114?

The interventions under investigation include: Screening, detection and referral for atrial fibrillation (DEVICE).

Who is sponsoring clinical trial NCT05067114?

This trial is sponsored by American Pharmacists Association Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05067114 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05067114's enrollment target sits among peer trials

650 81st of 300 higher than 218 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02934477 · 650 participants

    Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

  • NCT04579120 · 650 participants

    Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

  • NCT04875702 · 650 participants · Phase 4

    Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

  • NCT05046600 · 650 participants

    Registry of Arthrex Hand and Wrist Products

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05067114, the US trial registry maintained by the National Library of Medicine. NCT05067114 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.